My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Zee in spotlight after stellar Q4 financial performance
May 10,2017

The result was announced during market hours today, 10 May 2017.

Meanwhile, the S&P BSE Sensex was up 325.51 points or 1.09% at 30,258.76.

On the BSE, 2.74 lakh shares were traded on the counter so far as against the average daily volumes of 82,892 shares in the past one quarter. The stock had hit a high of Rs 521.50 and a low of Rs 496.30 so far during the day. The stock had hit a 52-week high of Rs 588.80 on 3 October 2016 and a 52-week low of Rs 405 on 9 May 2016.

The large-cap company has equity capital of Rs 96.04 crore. Face value per share is Re 1.

Zee Entertainment Enterprises Q4 March 2017 consolidated net profit was boosted by an exceptional income of Rs 1223.44 crore on account of sale of Sports Broadcasting Business to Sony Pictures Network.

Advertising revenue for Q4 March 2017 was Rs 846.90 crore. Domestic advertising revenue grew by 8.1% to Rs 794.40 crore while international advertising revenue stood at Rs 52.50 crore.

Subscription revenue fell 6.1% to Rs 558 crore in Q4 March 2017 over Q4 March 2016 due to high base on account of catch-up revenues in Q4 March 2016. Domestic subscription revenue stood at Rs 455.40 crore while international subscription revenue stood at Rs 102.60 crore.

Earnings before interest, tax, depreciation and amortization (EBITDA) rose 14% to Rs 468.70 crore in Q4 March 2017 over Q4 March 2016. EBITDA margin stood at 30.7%.

Zee Entertainment Enterprises said that after a couple of quarters of weakness, advertising growth appears to be back on track. The GST roll-out could boost advertising spends as a part of potential tax savings might be reinvested. While there is uncertainty regarding the implementation of the new tariff regulation due to pending litigations, the company has published the prices of its channels and bouquets. The company is confident that with the strong competitive position of channels in every genre, it will be able to drive subscription business.

Zee Entertainment Enterprises is one of Indias leading television media and entertainment companies. The company and its affiliate companies have leading presence across the media value chain including television broadcasting, cable distribution, direct-to-home satellite services, digital media and print media amongst others.

Powered by Capital Market - Live News

Kotak Mahindra Bank gains after shareholders OK raising foreign investment limit
May 10,2017

The announcement was made after market hours yesterday, 9 May 2017.

Meanwhile, the S&P BSE Sensex was up 323.32 points, or 1.08% to 30,256.57.

On the BSE, 77,000 shares were traded in the counter so far, compared with average daily volumes of 6.72 lakh shares in the past one quarter. The stock had hit a high of Rs 929 so far during the day, which is also a record high for the counter. The stock had hit a low of Rs 912 so far during the day. The stock hit a 52-week low of Rs 692.40 on 24 May 2016.

The stock had outperformed the market over the past one month till 9 May 2017, rising 3.57% compared with 1.21% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 18.17% as against Sensexs 5.81% rise.

The large-cap company has equity capital of Rs 920.51 crore. Face value per share is Rs 5.

Kotak Mahindra Bank said that its shareholders approved increasing ceiling limit of Foreign Institutional Investors (FIIs) and Foreign Portfolio Investors (FPIs) holding in the bank to 49% from existing 42%. Shareholders also approved issuing 6.20 crore shares via American Depository Receipt (ADR) or Global Depository Receipt (GDR) or other permissible securities convertible into equity shares.

Kotak Mahindra Banks net profit rose 40.34% to Rs 976.48 crore on 9.85% rise in total income to Rs 5434.65 crore in Q4 March 2017 over Q4 March 2016.

Kotak Mahindra Bank is one of the leading private sector banks in India.

Powered by Capital Market - Live News

Volumes jump at Federal-Mogul Goetze (India) counter
May 10,2017

Federal-Mogul Goetze (India) clocked volume of 2.23 lakh shares by 14:55 IST on BSE, a 71.33-times surge over two-week average daily volume of 3,000 shares. The stock rose 1.01% to Rs 596.

Piramal Enterprises notched up volume of 3.54 lakh shares, a 31.37-fold surge over two-week average daily volume of 11,000 shares. The stock rose 1.04% to Rs 2,516.

Gujarat Mineral Development Corporation saw volume of 12.23 lakh shares, a 26.56-fold surge over two-week average daily volume of 46,000 shares. The stock jumped 6.06% to Rs 133.05. Gujarat Mineral Development Corporations net profit jumped 135.81% to Rs 90.01 crore on 42.42% rise in total income to Rs 553.36 crore in Q4 March 2017 over Q4 March 2016. The Q4 result was announced after market hours yesterday, 9 May 2017.

HSIL clocked volume of 1.53 lakh shares, a 26.41-fold surge over two-week average daily volume of 6,000 shares. The stock rose 0.6% to Rs 346.15.

Cyient saw volume of 1.60 lakh shares, a 20.11-fold rise over two-week average daily volume of 8,000 shares. The stock rose 1.05% to Rs 537.65.

Powered by Capital Market - Live News

Marksans Pharma in pink of health after UK MHRA approval
May 10,2017

The announcement was made during market hours today, 10 May 2017.

Meanwhile, the BSE Sensex was up 290.72 points, or 0.97%, to 30,223.97. The S&P BSE Small-Cap index was up 122.15 points, or 0.79% to 15,666.78

On the BSE, so far 37.51 lakh shares were traded in the counter, compared with average daily volumes of 10.68 lakh shares in the past one quarter. The stock had hit a high of Rs 56.25 and a low of Rs 48.20 so far during the day. The stock hit a 52-week high of Rs 58.30 on 6 October 2016. The stock hit a 52-week low of Rs 36.95 on 1 February 2017.

The stock had underperformed the market over the past one month till 9 May 2017, sliding 4.27% compared with 1.21% rise in the Sensex. The scrip also underperformed the market in past one quarter, declining 14.02% as against Sensexs 5.81% rise.

The small-cap company has equity capital of Rs 40.93 crore. Face value per share is Re 1.

It may be recalled that Marksans Pharma had announced on 20 February 2017, that its Goa plants inspection by UK MHRA from 14 February 2017 to 17 February 2017 was completed without any critical observations.

Marksans Pharmas consolidated net profit fell 37% to Rs 11.30 crore on 1% decrease in net sales to Rs 215.24 in Q3 December 2016 over Q3 December 2015.

Marksans Pharma is a global pharmaceutical company. It is engaged in research & development (R&D) and offers CRAMS (contract research and manufacturing services) to global pharmaceutical companies.

Powered by Capital Market - Live News

Biocon slips after USFDA observations
May 10,2017

Meanwhile, the S&P BSE Sensex was up 273.51 points, or 0.91% to 30,206.76.

On the BSE, 2.04 lakh shares were traded in the counter so far, compared with average daily volumes of 64,781 shares in the past one quarter. The stock had hit a high of Rs 1,037.05 and a low of Rs 984.25 so far during the day. The stock hit a 52-week high of Rs 1,188 on 25 April 2017. The stock hit a 52-week low of Rs 610.40 on 10 May 2016.

The stock had underperformed the market over the past one month till 9 May 2017, falling 5.17% compared with 1.21% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 4.07% as against Sensexs 5.81% rise.

The large-cap bio-pharmaceutical company has equity capital of Rs 100 crore. Face value per share is Rs 5.

Biocon said observations on form 483 is a standard outcome of any audit. The company has already responded to US Food and Drug Administration (USFDA) on all observations of the recent audit within stipulated timelines. As a policy, the company does not comment on any schedule or outcomes of regulatory inspections, unless it believes that there is a material impact. Biocon has a good track record of inspections by the USFDA, European regulators and other regulators from developed and emerging markets, the company added.

On a consolidated basis, net profit of Biocon declined 61.71% to Rs 127.50 crore on 1.53% decline in net sales to Rs 919.20 crore in Q4 March 2017 over Q4 March 2016.

Biocon is Indias largest and fully-integrated, innovation-led biopharmaceutical company.

Powered by Capital Market - Live News

Nelco declines after weak Q4 results
May 10,2017

The result was announced after market hours yesterday, 9 May 2017.

Meanwhile, the S&P BSE Sensex was up 242.13 points, or 0.81% at 30,175.38. The S&P BSE Small-cap index was up 108.89 points, 0.7% at 15,653.52.

On the BSE, 47,000 shares were traded on the counter so far as against the average daily volumes of 34,490 shares in the past one quarter. The stock had hit a high of Rs 88.80 and a low of Rs 85.70 so far during the day.

The stock had hit a 52-week high of Rs 109.70 on 8 June 2016 and a 52-week low of Rs 68.40 on 22 November 2016. The stock had outperformed the market over the past one month till 9 May 2017, advancing 8.61% compared with the Sensexs 0.76% rise. The scrip had also outperformed the market over the past one quarter advancing 8.81% as against the Sensexs 5.66% rise.

The small-cap company has equity capital of Rs 22.82 crore. Face value per share is Rs 10.

Nelco offers solutions in the areas of integrated security & surveillance, VSAT connectivity (Tatanet VSAT), managed services, satcom projects and meteorological solutions. The company offers a range of innovative and customized solutions for businesses and government institutions under one roof.

Powered by Capital Market - Live News

Marksans Pharma leads gainers on BSEs A group
May 10,2017

Marksans Pharma rose 13.81% at Rs 54.80. The stock topped the gainers in A group. On the BSE, 32.21 lakh shares were traded on the counter so far as against the average daily volumes of 4.74 lakh shares in the past two weeks.

Gujarat Mineral Development Corporation (GMDC) rose 7.33% at Rs 134.65. The stock was the second biggest gainer in A group. On the BSE, 10.84 lakh shares were traded on the counter so far as against the average daily volumes of 46,000 shares in the past two weeks.

Escorts rose 7.04% at Rs 642. The stock was the third biggest gainer in A group. On the BSE, 9.69 lakh shares were traded on the counter so far as against the average daily volumes of 2.19 lakh shares in the past two weeks.

CG Power and Industrial Solutions rose 5.33% at Rs 87.95. The stock was the fourth biggest gainer in A group. On the BSE, 12.38 lakh shares were traded on the counter so far as against the average daily volumes of 3.29 lakh shares in the past two weeks.

Bharti Airtel rose 4.80% at Rs 362.10. The stock was the fifth biggest gainer in A group. On the BSE, 7.57 lakh shares were traded on the counter so far as against the average daily volumes of 1.16 lakh shares in the past two weeks.

Powered by Capital Market - Live News

Bitter pill for AstraZeneca Pharma after reverse turnaround in Q4
May 10,2017

The result was announced after market hours yesterday, 9 May 2017.

Meanwhile, the S&P BSE Sensex was up 263.29 points, or 0.88%, to 30,196.54. The S&P BSE Small-Cap index was up 130.87 points, or 0.84% to 15,675.50

On the BSE, 7,662 shares were traded on the counter so far as against the average daily volumes of 6,031 shares in the past one quarter. The stock had hit a high of Rs 968 and a low of Rs 945 so far during the day. The stock had hit a 52-week high of Rs 1,151 on 9 May 2016 and a 52-week low of Rs 909 on 1 March 2017.

The stock had outperformed the market over the past one month till 9 May 2017, rising 2.76% compared with 1.21% rise in the Sensex. The scrip, however, underperformed the market in past one quarter, gaining 5.09% as against Sensexs 5.81% rise.

The small-cap company has equity capital of Rs 5 crore. Face value per share is Rs 2.

AstraZeneca Pharma Indias total income dropped 26.66% to Rs 118.01 crore in Q4 March 2017 over Q4 March 2016.

AstraZeneca Pharma India is engaged in the development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. AstraZeneca Pharmaceuticals AB holds 75% stake in AstraZeneca Pharma India (as per the shareholding pattern as on 31 March 2017).

Powered by Capital Market - Live News

Flop show for Shemaroo Entertainment after poor Q4 result
May 10,2017

The result was announced after market hours yesterday, 9 May 2017.

Meanwhile, the S&P BSE Sensex was up 228.69 points, or 0.76% to 30,161.94. The S&P BSE Small-Cap index was up 117.11 points, or 0.75% to 15,661.74

On BSE, so far 38,000 shares were traded in the counter, compared with an average volume of 10,174 shares in the past one quarter. The stock hit a high of Rs 390.10 and a low of Rs 349.05 so far during the day. The stock hit a record high of Rs 439.45 on 23 January 2017. The stock hit a 52-week low of Rs 294 on 29 September 2016.

The stock had underperformed the market over the past one month till 9 May 2017, rising 0.1% compared with 1.21% rise in the Sensex. The scrip, however, underperformed the market in past one quarter, falling 4.1% as against Sensexs 5.81% rise.

The small-cap company has an equity capital of Rs 27.18 crore. Face value per share is Rs 10.

Shemaroo Entertainments EBITDA (earnings before interest, taxes, depreciation and amortization) decreased by 4.6% to Rs 32.36 crore in Q4 March 2017 over Q4 March 2016. EBITDA margin stood at 32.6% in Q4 March 2017 as against 33% in Q4 March 2016.

Hiren Gada, Wholetime Director and CFO, Shemaroo Entertainment said that the Q4 March 2017 traditional media business was affected due to ad slowdown post demonetization. The companys focus on digital media business has continued to yield positive results and it continues to strengthen the growth trajectory by adding quality content to library.

Shemaroo Entertainment is an established filmed entertainment Content House in the country, active in Content Ownership, Creation, Aggregation and Distribution with a large content library of over 3,400 titles. Shemaroo is engaged in the distribution of content for satellite channels, physical formats and emerging digital technologies like the Mobile, Internet, Broadband, IPTV and DTH among others.

Powered by Capital Market - Live News

Blue Star chills after strong Q4 outcome
May 10,2017

The result was announced after market hours yesterday, 9 May 2017.

Meanwhile, the S&P BSE Sensex was up 252.21 points or 0.84% at 30,185.46. The S&P BSE Mid-Cap index was up 133.72 points or 0.9% at 14,954.85

On BSE, so far 14,000 shares were traded in the counter as against average daily volume of 19,301 shares in the past one quarter. The stock hit a high of Rs 722.60 and a low of Rs 706 so far during the day. The stock had hit a record high of Rs 723.95 on 5 April 2017. The stock had hit a 52-week low of Rs 407.65 on 24 June 2016.

The stock had outperformed the market over the past one month till 9 May 2017, rising 5.47% compared with 1.21% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 29.65% as against Sensexs 5.81% rise.

The mid-cap company has equity capital of Rs 19.11 crore. Face value per share is Rs 2.

Blue Stars consolidated net profit rose 17.44% to Rs 123.05 crore on 15.53% growth in net sales to Rs 4,387.73 crore in the year ended 31 March 2017 (FY 2017) over FY 2016. Blue Star said that consequent to the corporate restructuring implemented in FY 2016, previous years numbers have been restated wherever required under IND AS and also to give effect to the restructuring. Therefore, the FY 2017 performance is not directly comparable with the previous years numbers.

The companys consolidated total operating income rose 22% to Rs 4424.72 crore for FY 2017 over FY 2016 (excluding BSILs operating income of Rs 205.09 crore). Operating Profit (PBIDTA excluding other non operating income) rose 20% Rs 256.99 crore in FY 2017 over FY 2016 (excluding BSILs PBIDTA of Rs 31.16 crores).

Other income (including finance income) rose 45.97% to Rs 34.58 crores in FY 2017 over FY 2016 (excluding BSILs other income of Rs 5.98 crore) mainly on account of higher interest on income tax refunds and net forex gain. There were no exceptional items during FY 2017 as compared to an exceptional expense of Rs 11.89 crore in FY 2016.

Carry forward order book as on 31 March 2017 grew by 21% to Rs 1940 crore in FY 2017 over FY 2016.

In its outlook, Blue Star said that while the electro-mechanical projects business continues to be adversely affected due to the slowdown in commercial construction, government-funded infrastructure projects have been witnessing some growth resulting in some traction in this segment. The unitary products business has been performing impressively driven by the companys strong brand equity and enhanced distribution footprint. Given the early onset of summer and the forecast of a normal monsoon coupled with addition of new product lines such as water purifiers and air purifiers, the prospects of this business look promising. Overall, the company is confident of sustaining its growth momentum in FY 2018 as well.

Blue Star is Indias leading central airconditioning company. The company fulfils the airconditioning needs of a large number of corporate, commercial and residential customers and has also established leadership in the field of commercial refrigeration.

Powered by Capital Market - Live News

Fertiliser shares in demand
May 10,2017

Chambal Fertilisers & Chemicals (up 10.05%), Rashtriya Chemicals and Fertilisers (up 7.83%), Fertilisers & Chemicals Travancore (up 5.41%), National Fertilizers (up 2.63%), Zuari Global (up 2.30%), Coromandel International (up 2.14%), Tata Chemicals (up 2.09%), Gujarat State Fertilizers & Chemicals (up 2.02%) and Deepak Fertilisers & Petrochemicals Corporation (up 0.67%), edged higher.

The S&P BSE Sensex was up 229.94 points, or 0.77% at 30,163.19.

India looks likely to receive above average monsoon rainfall as concern over the El Nino weather condition has eased in the past few weeks, India Meteorological Department (IMD) Director General KJ Ramesh was quoted by the media yesterday, 9 May 2017, raising prospects of higher farm and economic growth.

The IMD on 18 April 2017 forecast this years monsoon rains at 96% of a 50-year average of 89 cm. El Nino is a phenomenon associated with warming of ocean surface temperatures in the eastern and central Pacific that typically occurs every few years.

However, Ramesh reportedly denied the possibility that monsoon would be above normal this year. Anything between 96% and 104% of the long period average (LPA) is considered as normal. Anything under 96% is considered as below normal and 104-110% of the LPA as above normal.

Powered by Capital Market - Live News

Jubilant Life Sciences gains after resuming Gajraula operations
May 10,2017

The announcement was made after market hours yesterday, 9 May 2017.

Meanwhile, the S&P BSE Sensex was up 245.10 points, or 0.82% to 30,178.35.

On the BSE, 55,000 shares were traded in the counter so far, compared with average daily volumes of 99,595 shares in the past one quarter. The stock had hit a high of Rs 797.95 and a low of Rs 774 so far during the day. The stock hit a record high of Rs 879.10 on 12 April 2017. The stock hit a 52-week low of Rs 294.20 on 24 June 2016.

The stock had underperformed the market over the past one month till 9 May 2017, falling 5.32% compared with 1.21% rise in the Sensex. The scrip had, however, outperformed the market in past one quarter, rising 9.49% as against Sensexs 5.81% rise.

The large-cap company has equity capital of Rs 15.93 crore. Face value per share is Re 1.

The National Green Tribunal (NGT) has passed an order allowing the company to restart manufacturing operations in all its units at Gajraula (except the distillery unit) in compliance with the directions issued by the NGT in this regard. The company said it has complied with the directions issued by NGT and has, with effect from yesterday, 9 May 2017, restarted its manufacturing operations in Gajraula (except the distillery unit). The revenue impact of the distillery operations in financial year ended March (FY 2017) is not significant.

The company said it operates its manufacturing facilities in Gajraula with zero liquid discharge. In 2016, the companys manufacturing facilities in Gajraula were awarded the gold category for their sustainability performance and were rated amongst the top 5% global performers as evaluated by EcoVadis during its latest evaluation.

The company assured that all its manufacturing facilities including those at Gajraula comply with all applicable laws.

On 27 April 2017, Jubilant Life Sciences informed that NGT ordered 13 industrial units situated in Gajraula to immediately cease operations after a hearing on Ganga pollution case.

On a consolidated basis, Jubilant Life Sciences net profit fell 2.6% to Rs 119.78 crore on 8.7% rise in net sales to Rs 1438.81 crore in Q3 December 2016 over Q3 December 2015.

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients and drug discovery solutions. The pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma, is engaged in manufacture and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile and non-sterile products through 6 USFDA approved manufacturing facilities in India, USA and Canada.

Powered by Capital Market - Live News

Peninsula Land declines after reverse turnaround in Q4
May 10,2017

The result was announced after market hours yesterday, 9 May 2017.

Meanwhile, the S&P BSE Sensex was up 268.91 points, or 0.9% at 30,202.16. The S&P BSE Small-cap index was up 141.10 points, 0.91% at 15,685.73.

High volumes were traded on the counter. On the BSE, 4.41 lakh shares were traded on the counter so far as against the average daily volumes of 2.75 lakh shares in the past one quarter. The stock had hit a high of Rs 25.45 and a low of Rs 23.50 so far during the day.

The stock had hit a 52-week high of Rs 30.20 on 18 April 2017 and a 52-week low of Rs 13.15 on 27 December 2016. The stock had outperformed the market over the past one month till 9 May 2017, advancing 9.09% compared with the Sensexs 0.76% rise. The scrip had also outperformed the market over the past one quarter advancing 55.84% as against the Sensexs 5.66% rise.

The small-cap company has equity capital of Rs 55.84 crore. Face value per share is Rs 2.

Peninsula Lands total income spurted 200% to Rs 2.55 crore in Q4 March 2017 over Q4 March 2016.

Shares of Peninsula Land had witnessed an impressive rally prior to the announcement of the companys results. The stock had surged 16.56% in the preceding two trading sessions to settle at Rs 26.40 yesterday, 9 May 2017, from its closing of Rs 22.65 on 5 May 2017.

Peninsula Land is the real estate arm of Ashok Piramal Group. The company is known for its concept based architectures in the commercial, retail and residential sectors.

Powered by Capital Market - Live News

IDBI Bank slips after RBI action
May 10,2017

The announcement was made after market hours yesterday, 9 May 2017.

Meanwhile, the S&P BSE Sensex was up 239.74 points, or 0.80% to 30,172.99.

On the BSE, 3.44 lakh shares were traded in the counter so far, compared with average daily volumes of 5.53 lakh shares in the past one quarter. The stock had hit a high of Rs 80.85 and a low of Rs 79.10 so far during the day. The stock hit a 52-week high of Rs 86.50 on 6 February 2017. The stock hit a 52-week low of Rs 62.95 on 9 November 2016.

The stock had outperformed the market over the past one month till 9 May 2017, rising 9.05% compared with 1.21% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 0.85% as against Sensexs 5.81% rise.

The large-cap company has equity capital of Rs 2058.82 crore. Face value per share is Rs 10.

The Reserve Bank of India (RBI), vide their letter dated 5 May 2017, initiated prompt corrective action for IDBI Bank in view of high net non-performing assets (NPA) and negative return on assets (ROA). This action will not have any material impact on the performance of the bank and will contribute to improving the internal controls of the bank and improvement in its activities, IDBI Bank said in a statement.

IDBI Bank reported net loss of Rs 2254.96 crore in Q3 December 2017, higher than net loss of Rs 2183.68 crore in Q3 December 2016. Operating income fell 3.5% to Rs 7104.21 crore in Q3 December 2016 over Q3 December 2015.

Government of India holds 73.98% stake in IDBI Bank (as on 31 March 2017).

Powered by Capital Market - Live News

Petronet LNG gains after strong Q4 result, bonus shares
May 10,2017

The announcement was made after market hours yesterday, 9 May 2017.

Meanwhile, the S&P BSE Sensex was up 258.66 points, or 0.86% to 30,192.11

On the BSE, 2.09 lakh shares were traded in the counter so far, compared with average daily volumes of 2.04 lakh shares in the past one quarter. The stock had hit a high of Rs 448.60 and hit a low of Rs 434.50 so far during the day. The stock hit a record high of Rs 453.65 on 21 April 2017. The stock hit a 52-week low of Rs 253.10 on 24 May 2016.

The stock had outperformed the market over the past one month till 9 May 2017, rising 3.85% compared with 1.21% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 14.09% as against Sensexs 5.81% rise.

The large-cap company has equity capital of Rs 750 crore. Face value per share is Rs 10.

Petronet LNGs net profit surged 93.74% to Rs 470.79 crore on 20.87% increase in net sales to Rs 7,191.99 crore in Q4 March 2017 over Q4 March 2016. The result was announced after market hours yesterday, 9 May 2017.

Petronet LNG was formed as a joint venture by the Government of India to import liquified natural gas (LNG) and set up LNG terminals in the country.

Powered by Capital Market - Live News